UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Breast cancer assessment tools and optimizing adjuvant therapy

Nature reviews. Clinical oncology, 2010-12, Vol.7 (12), p.725-732

2010

Volltextzugriff (PDF)

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Journal of thoracic oncology, 2022-01, Vol.17 (1), p.103-115

2022

Volltextzugriff (PDF)

Progress in nonviral gene therapy for breast cancer and what comes next?

Expert opinion on biological therapy, 2017-05, Vol.17 (5), p.595-611

2017

Volltextzugriff (PDF)

Abstract P5-02-04: Immune Signatures Display Subtype-Specific Activation in Breast Cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P5-P5-02-04

2023

Volltextzugriff (PDF)

Lymphocytic hypophysitis: differential diagnosis and effects of high-dose pulse steroids, followed by azathioprine, on the pituitary mass and endocrine abnormalities--report of a case and literature review

TheScientificWorld, 2010-01, Vol.10, p.126-134

2010

Volltextzugriff (PDF)

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

Nature reviews. Clinical oncology, 2013-07, Vol.10 (7), p.377-389

2013

Volltextzugriff (PDF)

Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1108-TPS1108

2022

Volltextzugriff (PDF)

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers

Breast cancer research : BCR, 2016-12, Vol.18 (1), p.121-121, Article 121

2016

Volltextzugriff (PDF)

miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4), p.927-939

2016

Volltextzugriff (PDF)

HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS1115-TPS1115

2023

Volltextzugriff (PDF)

Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers

Current pharmaceutical design, 2012-12, Vol.19 (5), p.864-882

2012

Volltextzugriff (PDF)

Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes

International journal of cancer, 2016-01, Vol.138 (1), p.87-97

2016

Volltextzugriff (PDF)

Long-term Eradication of Locally Recurrent Invasive Follicular Thyroid Carcinoma after Taxane-based Concomitant Chemoradiotherapy

Anticancer research, 2009-11, Vol.29 (11), p.4665-4671

2009

Volltextzugriff (PDF)

Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1096-1096

2017

Volltextzugriff (PDF)

Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients

Cancer, 2012-05, Vol.118 (10), p.2603-2614

2012

Volltextzugriff (PDF)

Targeting triple negative breast cancer: Is p53 the answer?

Cancer treatment reviews, 2013-08, Vol.39 (5), p.541-550

2013

Volltextzugriff (PDF)

Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer

The oncologist (Dayton, Ohio), 2016-09, Vol.21 (9), p.1063-1078

2016

Volltextzugriff (PDF)

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes

British journal of cancer, 2018-04, Vol.118 (8), p.1107-1114

2018

Volltextzugriff (PDF)

Uncovering the metabolomic fingerprint of breast cancer

The international journal of biochemistry & cell biology, 2011-07, Vol.43 (7), p.1010-1020

2011

Volltextzugriff (PDF)

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

Oncotarget, 2015-11, Vol.6 (35), p.37269-37280

2015

Volltextzugriff (PDF)

Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer

Cell cycle (Georgetown, Tex.), 2013-06, Vol.12 (11), p.1679-1687

2013

Volltextzugriff (PDF)

Notch is a direct negative regulator of the DNA-damage response

Nature structural & molecular biology, 2015-05, Vol.22 (5), p.417-424

2015

Volltextzugriff (PDF)

Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer

JNCI : Journal of the National Cancer Institute, 2011-02, Vol.103 (3), p.264-272

2011

Volltextzugriff (PDF)

Erratum to “Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma” [Hum Pathol 40 (2009) 827-833]

Human pathology, 2009-08, Vol.40 (8), p.1212-1212

2009

Volltextzugriff (PDF)

Targeting the microRNA-regulating DNA damage/repair pathways in cancer

Expert opinion on biological therapy, 2014-11, Vol.14 (11), p.1667-1683

2014

Volltextzugriff (PDF)

26 – 50 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(84)

Publikationsform

Sprache

Englisch
(101)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(65)
Science & Technology
(65)
Humans
(59)
Oncology
(39)
Female
(36)
Breast Cancer
(29)
Breast Neoplasms - Genetics
(17)
Breast Neoplasms - Drug Therapy
(15)
Breast Neoplasms - Pathology
(15)
Prognosis
(15)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Tumors
(14)
Adult
(12)
Endocrinology & Metabolism
(12)
Mutation
(12)
Breast Neoplasms - Metabolism
(10)
Gene Expression Regulation, Neoplastic
(10)
Animals
(9)
Antineoplastic Agents - Therapeutic Use
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Breast cancer assessment tools and optimizing adjuvant therapy

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Progress in nonviral gene therapy for breast cancer and what comes next?

Abstract P5-02-04: Immune Signatures Display Subtype-Specific Activation in Breast Cancer

Lymphocytic hypophysitis: differential diagnosis and effects of high-dose pulse steroids, followed by azathioprine, on the pituitary mass and endocrine abnormalities--report of a case and literature review

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers

miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer

HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer

Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers

Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes

Long-term Eradication of Locally Recurrent Invasive Follicular Thyroid Carcinoma after Taxane-based Concomitant Chemoradiotherapy

Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability

Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients

Targeting triple negative breast cancer: Is p53 the answer?

Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes

Uncovering the metabolomic fingerprint of breast cancer

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer

Notch is a direct negative regulator of the DNA-damage response

Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer

Erratum to “Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma” [Hum Pathol 40 (2009) 827-833]

Targeting the microRNA-regulating DNA damage/repair pathways in cancer

Suchergebnisse filtern